Samuel Allen, DO
Pulmonary Disease · Troy, MINPI 1306861414
Payments from drug & device makers
Across 606 payments — averaging $652.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$188K
- Janssen Research & Development, LLC$71K
- United Therapeutics Corporation$50K
- Bayer$41K
- Actelion Pharmaceuticals, Ltd$21K
- Merck$15K
- plus $8K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 203 | $188,237 |
| Janssen Research & Development, LLC | 23 | $70,789 |
| United Therapeutics Corporation | 68 | $50,321 |
| Bayer | 34 | $41,432 |
| Actelion Pharmaceuticals, Ltd | 7 | $21,075 |
| Merck | 19 | $14,926 |
| AstraZeneca | 101 | $2,972 |
| Medical Device Business Services, Inc. | 17 | $1,920 |
| GSK | 47 | $809 |
| Johnson & Johnson(2 entities) | 12 | $450 |
| Insmed, Inc. | 16 | $444 |
| Sanofi | 3 | $348 |
| Verona Pharma, Inc. | 23 | $313 |
| Intuitive Surgical | 1 | $144 |
| Regeneron Healthcare Solutions, Inc. | 3 | $125 |
| Boehringer Ingelheim | 2 | $122 |
| AbbVie | 2 | $111 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $70 |
| Electromed, Inc. | 5 | $66 |
| Gilead | 4 | $55 |
| Pulmonx Corporation | 2 | $55 |
| Mylan Specialty L.p. | 2 | $47 |
| E.r. Squibb & Sons, L.L.C. | 2 | $42 |
| Sunovion Pharmaceuticals Inc. | 3 | $42 |
| Baxter Healthcare | 1 | $37 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Circassia Inc. | 1 | $18 |
| Sandoz | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
How this compares
$395,113 in reported general payments places this provider in the 95th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Troy
- Njira LugogoAnn Arbor$12.9M
- Timothy BlackwellAnn Arbor$2.5M
- Kevin FlahertyAnn Arbor$2.3M
- Meilan HanAnn Arbor$1.8M
- Gary FergusonLivonia$1.5M
- Justin OldhamAnn Arbor$1.4M
- Robert PaineAnn Arbor$1.3M
- Irina ShanidzeFarmington Hills$1.2M
- Oscar Parodi Ortiz de VillateWarren$1.1M
- Yvonne HuangAnn Arbor$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.